SymBio Pharmaceuticals
4582.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | ¥1.3bn | ¥2.5bn | ¥5.6bn | ¥10.0bn | — |
| Operating income | −¥4.4bn | −¥3.9bn | −¥812m | ¥2.0bn | — |
| Ordinary income | −¥4.6bn | −¥3.7bn | −¥736m | ¥2.0bn | — |
| Net income (owners) | −¥4.8bn | −¥3.8bn | −¥2.0bn | ¥1.2bn | — |
| Total assets | ¥3.9bn | ¥5.0bn | ¥8.2bn | ¥10.4bn | — |
| Net assets / equity | ¥1.3bn | ¥4.2bn | ¥7.2bn | ¥8.5bn | ¥6.7bn |
| Operating cash flow | −¥4.6bn | −¥3.4bn | −¥195m | ¥1.6bn | — |
| EPS (basic) | ¥-95.12 | ¥-85 | ¥-49.19 | ¥30.2 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 67 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 178 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 67 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 169 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 67 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 44 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 160 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 47 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 71 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 46 figures · EDINET |
| 2022-01-01 → 2022-12-31 | AnnualAmended | 131 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 131 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 20 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 30 figures · EDINET |
22 more reports are still being processed.